| Literature DB >> 19589888 |
Hélène Maillard-Lefebvre1, Eric Boulanger, Maïté Daroux, Cédric Gaxatte, Barry I Hudson, Marc Lambert.
Abstract
The formation of advanced glycation end products (AGEs) is a result of the non-enzymatic reaction between sugars and free amino groups of proteins. AGEs, through interacting with their specific receptor for AGEs (RAGE), result in activation of pro-inflammatory states and are involved in numerous pathologic situations. The soluble form of RAGE (sRAGE) is able to act as a decoy to avoid interaction of RAGE with its pro-inflammatory ligands (AGEs, HMGB1, S100 proteins). sRAGE levels have been found to be decreased in chronic inflammatory diseases including atherosclerosis, diabetes, renal failure and the aging process. The use of measuring circulating sRAGEs may prove to be a valuable vascular biomarker and in this review, we describe the implications of sRAGE in inflammation and propose that this molecule may represent a future therapeutic target in chronic inflammatory diseases.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19589888 DOI： 10.1093/rheumatology/kep199
Source DB: PubMed Journal: Rheumatology (Oxford) ISSN： 1462-0324 Impact factor: 7.580